1-11 of 11
combined modality therapy
Close
Sort by
Journal Articles

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death

Eva De Smedt, Julie Devin, Catharina Muylaert, Nicolas Robert, Guilhem Requirand, Philip Vlummens, Laure Vincent, Guillaume Cartron, Ken Maes, Jerome Moreaux, Elke De Bruyne
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2325–2338.
https://doi.org/10.1182/bloodadvances.2020003217
Published: 2021
Includes: Supplemental data
Journal Articles

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

Christie P. M. Verkleij, Marloes E. C. Broekmans, Mark van Duin, Kristine A. Frerichs, Rowan Kuiper, A. Vera de Jonge, Martin Kaiser, Gareth Morgan, Amy Axel, Rengasamy Boominathan, Jocelyn Sendecki, Amy Wong, Raluca I. Verona, Pieter Sonneveld, Sonja Zweegman, Homer C. Adams, III, Tuna Mutis, Niels W. C. J. van de Donk
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2196–2215.
https://doi.org/10.1182/bloodadvances.2020003805
Published: 2021
Includes: Supplemental data
Journal Articles

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Clinical Trials & Observations
Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao, Jacob Glass, Amber C. King, Anthony F. Daniyan, Christopher Famulare, Bernadette M. Cuello, Troy Z. Horvat, Omar Abdel-Wahab, Ross L. Levine, Aaron D. Viny, Eytan M. Stein, Sheng F. Cai, Mikhail Roshal, Martin S. Tallman, Aaron D. Goldberg
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1552–1564.
https://doi.org/10.1182/bloodadvances.2020003734
Published: 2021
Includes: Supplemental data
Journal Articles

Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death

Debora Soncini, Paola Minetto, Claudia Martinuzzi, Pamela Becherini, Valeria Fenu, Fabio Guolo, Katia Todoerti, Giovanni Calice, Paola Contini, Maurizio Miglino, Giulia Rivoli, Sara Aquino, Alida Dominietto, Antonia Cagnetta, Mario Passalacqua, Santina Bruzzone, Alessio Nencioni, Massimo Zucchetti, Tommaso Ceruti, Antonino Neri, Roberto M. Lemoli, Michele Cea
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4312–4326.
https://doi.org/10.1182/bloodadvances.2020001639
Published: 2020
Includes: Supplemental data
Journal Articles

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

Clinical Trials & Observations
Je-Hwan Lee, Stefan Faderl, John M. Pagel, Chul Won Jung, Sung-Soo Yoon, Animesh D. Pardanani, Pamela S. Becker, Howard Lee, Jeongeun Choi, Kyoungjune Lee, Minkyoung Kim, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2020) 4 (9): 2032–2043.
https://doi.org/10.1182/bloodadvances.2019000757
Published: 2020
Includes: Supplemental data
Journal Articles

Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors

Clinical Trials & Observations
Christine E. Ryan, Matthew P. Cheng, Nicolas C. Issa, Jennifer R. Brown, Matthew S. Davids
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1458–1463.
https://doi.org/10.1182/bloodadvances.2020001678
Published: 2020
Journal Articles

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance

Joshua W. D. Tobin, Gabrielle Rule, Katherine Colvin, Lourdes Calvente, David Hodgson, Stephen Bell, Chengetai Dunduru, James Gallo, Erica S. Tsang, Xuan Tan, Jonathan Wong, Jessica Pearce, Robert Campbell, Shao Tneh, Sophie Shorten, Melissa Ng, Tara Cochrane, Constantine S. Tam, Emad Abro, Eliza Hawkes, Georgina Hodges, Roopesh Kansara, Dipti Talaulikar, Michael Gilbertson, Anna M. Johnston, Kerry J. Savage, Diego Villa, Kirk Morris, Sumi Ratnasingam, Wojt Janowski, Robert Kridel, Chan Y. Cheah, Michael MacManus, Nicholas Matigian, Peter Mollee, Maher K. Gandhi, Greg Hapgood
Journal: Blood Advances
Blood Adv (2019) 3 (19): 2804–2811.
https://doi.org/10.1182/bloodadvances.2019000458
Published: 2019
Includes: Supplemental data
Journal Articles

Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model

Chandini M. Thirukkumaran, Zhong Qiao Shi, Gerard J. Nuovo, Joanne Luider, Karen A. Kopciuk, Yuan Dong, Ahmed A. Mostafa, Satbir Thakur, Kathy Gratton, Ailian Yang, Alex C. Chin, Matt C. Coffey, Victor H. Jimenez-Zepeda, Douglas Stewart, Marta Chesi, P. Leif Bergsagel, Don Morris
Journal: Blood Advances
Blood Adv (2019) 3 (5): 797–812.
https://doi.org/10.1182/bloodadvances.2018025593
Published: 2019
Includes: Supplemental data
Journal Articles

Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL

Clinical Trials & Observations
Ina-Katrin Siekmann, Kevin Dierck, Sebastian Prall, Marianne Klokow, Julia Strauss, Sophia Buhs, Antonina Wrzeszcz, Michael Bockmayr, Florian Beck, Magdalena Trochimiuk, Kristina Gottschling, Victoria Martens, Melissa Khosh-Naucke, Helwe Gerull, Jürgen Müller, Lena Behrmann, Martin Blohm, René P. Zahedi, Irmela Jeremias, Albert Sickmann, Peter Nollau, Martin A. Horstmann
Journal: Blood Advances
Blood Adv (2018) 2 (19): 2554–2567.
https://doi.org/10.1182/bloodadvances.2018020693
Published: 2018
Includes: Supplemental data
Journal Articles

In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1 + BCP-ALL

Eleanor R. C. Fiedler, Arjun Bhutkar, Emily Lawler, Rana Besada, Michael T. Hemann
Journal: Blood Advances
Blood Adv (2018) 2 (11): 1229–1242.
https://doi.org/10.1182/bloodadvances.2017015610
Published: 2018
Includes: Supplemental data
Journal Articles

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma

Reid W. Merryman, Philippe Armand, Kyle T. Wright, Scott J. Rodig
Journal: Blood Advances
Blood Adv (2017) 1 (26): 2643–2654.
https://doi.org/10.1182/bloodadvances.2017012534
Published: 2017